Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 24 September 1999:
Vol. 285. no. 5436, pp. 2039 - 2042
DOI: 10.1126/science.285.5436.2039c
Prev | Table of Contents | Next

News of the Week

AIDS THERAPY:
Ambitious Clinical Trial Stirs Debate

Jon Cohen

The National Institute of Allergy and Infectious Diseases last week decided to fund what will likely be the largest and most expensive trial of an AIDS treatment the institute has ever backed, involving 210 sites in 18 countries. During the next 5 years, the $43 million study will follow 4000 HIV-infected people who are already taking anti-HIV drugs to see whether adding an immune-system messenger called interleukin-2 can help prevent disease and death. But some members of the AIDS research community believe the trial's flexible design and relatively healthy subjects may blur any results.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)